Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flexion Therapeutics Inc    FLXN

FLEXION THERAPEUTICS INC (FLXN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
23.22(c) 23.69(c) 24.41(c) 24.58(c) 23.19(c) Last
544 462 423 364 535 793 457 189 629 694 Volume
+5.93% +2.02% +3.04% +0.70% -5.66% Change
More quotes
Financials ($)
Sales 2017 0,54 M
EBIT 2017 -120 M
Net income 2017 -123 M
Finance 2017 287 M
Yield 2017 -
Sales 2018 28,2 M
EBIT 2018 -138 M
Net income 2018 -142 M
Finance 2018 195 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 1 081x
EV / Sales2018 24,0x
Capitalization 871 M
More Financials
Company
Flexion Therapeutics, Inc. is a pharmaceutical company, which focuses on the development and commercialization of novel, local therapies.The firm specializes in treatment of patients with musculoskeletal conditions including osteoarthritis.It offers products under the Zilretta brand.The company... 
Sector
Biotechnology & Medical Research
Calendar
02/21 | 04:00pmPresentation
More about the company
Surperformance© ratings of Flexion Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEXION THERAPEUTICS INC
02/14Flexion Therapeutics to Present at the RBC Capital Markets 2018 Global Health..
GL
02/03FLEXION THERAPEUTICS : Reports Inducement Grants Under NASDAQ Listing Rule 5635(..
AQ
02/02FLEXION THERAPEUTICS : Reports Inducement Grants Under NASDAQ Listing Rule 5635(..
AQ
01/19THERMO FISHER SCIENTIFIC : Designs Flexible Manufacturing Site for Flexion Thera..
AQ
01/09FLEXION THERAPEUTICS : Announces Initial Data from Clinical Trial Evaluating Rep..
AQ
01/08FLEXION THERAPEUTICS : Announces Initial Data from Clinical Trial Evaluating Rep..
AQ
2017FLXN Steers SHIP, NVAX To Report Data In Feb, FDA Nod For AERI, Spectral Shin..
AQ
2017Flexion Therapeutics Enrolls First Patient in Study Evaluating the Pharmacoki..
GL
2017Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Ost..
GL
2017FLEXION THERAPEUTICS : Announces Appointment of Scott Kelley, M.D. as Chief Medi..
AQ
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
02/15Flexion Therapeutics $FLXN Given News Impact Score of 0.25  
02/14Flexion Therapeutics to Present at the RBC Capital Markets 2018 Global Health.. 
02/11Alps Advisors Inc. Purchases 10,176 Shares of Flexion Therapeutics Inc $FLXN .. 
02/08Want automatic email alerts for $CNCE $FLXN $RRD $NGHC $INGN? Subscribe to Ma.. 
02/08New Research: Key Drivers of Growth for Radian Group, Flexion Therapeutics, A.. 
More tweets
Qtime:98
News from SeekingAlpha
02/16Key events next week - healthcare 
02/14PolyPid Files To Raise $86 Million In U.S. IPO 
02/082 Small Biotechs To Buy On This Dip 
02/02Gene therapy players under early pressure 
02/01Premarket analyst action - healthcare 
Chart FLEXION THERAPEUTICS INC
Duration : Period :
Flexion Therapeutics Inc Technical Analysis Chart | FLXN | US33938J1060 | 4-Traders
Technical analysis trends FLEXION THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 38,8 $
Spread / Average Target 67%
EPS Revisions
Managers
NameTitle
Michael D. Clayman President, Chief Executive Officer, CFO & Director
Patrick J. Mahaffy Chairman
Neil Bodick Chief Scientific Officer
Scott D. Kelley Chief Medical Officer
Yamo Deniz Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
FLEXION THERAPEUTICS INC-1.84%916
GILEAD SCIENCES14.21%106 851
VERTEX PHARMACEUTICALS4.94%39 772
REGENERON PHARMACEUTICALS-12.04%35 529
BIOVERATIV INC91.99%11 201
GENMAB4.28%11 055